Navigation Links
National Stroke Association Teams With Clinical Trial Matching Service CureLauncher
Date:7/23/2013

Bloomfrield Hills, MI (PRWEB) July 23, 2013

Michigan-based CureLauncher (http://www.curelauncher.com), developer of a patent-pending and proprietary clinical trial matching service, today announced an exclusive partnership with the National Stroke Association—a leading educational, prevention and advocacy group for individuals and their families and health care professionals confronting health issues related to strokes.

National Stroke Association members and visitors will be directed to http://www.curelauncher.com, where specially trained relationship managers help individuals find a clinical trial that may offer access to a new diagnostic test, treatment or rehabilitative approach.

“We are thrilled to partner with CureLauncher,” said Jim Baranski, National Stroke Association CEO. “Together, we can make progress in preventing, treating and understanding this challenging condition that impacts so many American families. In particular, clinical medical research is bringing us new diagnostic techniques to identify individuals at risk for stroke, as well as life strategies and other approaches to prevention.”

The power of clinical trials. Nearly 200 million Americans have a chronic disease such as diabetes, heart disease, asthma or cancer. Less than five percent of them know where to find new treatments available in clinical trials according to the Center for Information & Study on Clinical Research Participation (CISCRP). Yet, some of America’s best medical care is available through these clinical trials.

"CureLauncher redefines the approach to clinical trials by putting people and their families first," said David Fuehrer, CureLauncher President, who is also a two-time cancer survivor and active speaker and volunteer for various support communities.

“We are excited to collaborate with the National Stroke Association. We want to help them in their quest to prevent or alleviate what is now the nation’s fourth leading cause of death,” Fuehrer added.

About National Stroke Association:
The National Stroke Association was formed in 1984 to fill a void as the only national nonprofit healthcare organization focusing 100 percent of its resources and attention on stroke. In its brief history, National Stroke Association has become a leading national resource on stroke and the driving force behind efforts to improve stroke prevention, treatment, rehabilitation and support for all impacted by stroke. Learn more at: http://www.nationalstrokeassociation.com.

About CureLauncher:
CureLauncher gives people the power and support to make a life-changing decision. Its patent-pending matching system helps people find treatment options that are aligned with their unique goals and conditions. Take Control. Know Your Options™. Learn more at http://www.CureLauncher.com.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10954941.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. UV Flu Technologies Expands Its International Footprint
2. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
3. International Attendance for Networking and Education at Informex Beyond Manufacturing
4. Sundberg Kicks Off National Expansion With Openings of New Headquarters, Logistically Centric Mega Warehouses
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
7. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
8. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
9. PAREXEL International to Present at J.P. Morgan Healthcare Conference
10. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
11. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and NEW YORK , ... Lumeon , a leading digital health company, ... a provider of telemedicine and remote patient monitoring, ... for telemedicine reimbursements.  DN Telehealth ... patients, in real-time, extending consultations beyond a physical ...
(Date:2/23/2017)... Atlanta, it seems everyone has a chance to express their ... expressive and dynamic community unlike any other. The businesses that ... With their newest salon in ... on that tradition with a unique, fresh approach to head ... the newest of 13 nationwide locations, each of them well-situated ...
(Date:2/23/2017)... Ind. (PRWEB) , ... February 23, 2017 , ... ... Award during the 12th annual Inventors Recognition Reception at Purdue Research Park ... to a faculty member in recognition of outstanding contributions to, and success with, ...
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
Breaking Biology Technology:
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):